- Home
- ICCC vs OCX Comparison
ICCC vs OCX Comparison
Compare ICCC & OCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- OCX
- Stock Information
- Founded
- ICCC 1982
- OCX 2009
- Country
- ICCC United States
- OCX United States
- Employees
- ICCC N/A
- OCX N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ICCC Health Care
- OCX Health Care
- Exchange
- ICCC Nasdaq
- OCX Nasdaq
- Market Cap
- ICCC 39.2M
- OCX 35.1M
- IPO Year
- ICCC 1987
- OCX N/A
- Fundamental
- Price
- ICCC $5.02
- OCX $2.65
- Analyst Decision
- ICCC
- OCX Buy
- Analyst Count
- ICCC 0
- OCX 3
- Target Price
- ICCC N/A
- OCX $4.42
- AVG Volume (30 Days)
- ICCC 4.1K
- OCX 87.8K
- Earning Date
- ICCC 02-25-2025
- OCX 04-11-2025
- Dividend Yield
- ICCC N/A
- OCX N/A
- EPS Growth
- ICCC N/A
- OCX N/A
- EPS
- ICCC N/A
- OCX N/A
- Revenue
- ICCC $23,838,001.00
- OCX $709,000.00
- Revenue This Year
- ICCC N/A
- OCX N/A
- Revenue Next Year
- ICCC N/A
- OCX $106.34
- P/E Ratio
- ICCC N/A
- OCX N/A
- Revenue Growth
- ICCC 46.37
- OCX N/A
- 52 Week Low
- ICCC $3.34
- OCX $1.92
- 52 Week High
- ICCC $5.82
- OCX $3.48
- Technical
- Relative Strength Index (RSI)
- ICCC 47.31
- OCX 64.49
- Support Level
- ICCC $4.84
- OCX $2.21
- Resistance Level
- ICCC $5.25
- OCX $2.85
- Average True Range (ATR)
- ICCC 0.27
- OCX 0.22
- MACD
- ICCC -0.04
- OCX 0.07
- Stochastic Oscillator
- ICCC 27.27
- OCX 77.90
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.